Sutro Biopharma Q2 GAAP EPS misses by $0.14, revenue misses by $1.2M

Earnings
โดย Seeking Alpha·US·Read original
Summary · why it matters

Sutro Biopharma reported second-quarter 2026 financial results that fell short of expectations. The company posted a GAAP loss of $2.33 per share, missing consensus estimates by $0.14. Revenue came in at $9.84 million, an 84.6% decline year-over-year, and missed forecasts by $1.2 million.

Impact on stocks 1

Biotech & Genomic Medicine▼ · 1 stocks
Sutro Biopharma
STRO
▼ NegativeCapitalrelevance

Q2 GAAP EPS and revenue missed estimates, with revenue down 84.6% YoY.

© 2026 MarketDXNews